- Investing.com
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, and commercial organizations in the United States. The company operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, federal, and corporate management services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Analyst Outlook | Price targets range from $30 to $90, averaging $59.80, reflecting varied views on Centene's ability to navigate regulatory uncertainties and operational challenges |
Medicare Momentum | Learn how Centene's Medicare Advantage segment shows promise, leveraging experience to capitalize on demographic trends and market expansion |
Exchange Volatility | Delve into the ACA Exchange market's impact on Centene, including higher member acuity and potential subsidy changes affecting profitability |
Medicaid Dominance | Explore Centene's leading position in Medicaid managed care, its core strength amid challenges in cost management and rate negotiations |
Metrics to compare | CNC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCNCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.2x | −16.7x | −0.6x | |
PEG Ratio | 0.01 | −0.06 | 0.00 | |
Price / Book | 1.1x | 4.0x | 2.6x | |
Price / LTM Sales | 0.1x | 0.7x | 3.4x | |
Upside (Analyst Target) | −5.0% | 3.4% | 42.5% | |
Fair Value Upside | Unlock | 20.0% | 5.8% | Unlock |